Amgen
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Amgen sits in the top decile of US sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count).
Amgen: 558 sponsored US clinical trials, 55 recruiting.
Amgen sponsors 558 registered US clinical trials on ClinicalTrials.gov, 55 of them currently recruiting, and 373 completed. 212 of these trials are in Phase 3-4 (later-stage) and 327 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 8 trials.
Top-decile sponsor footprint
Amgen ranks in the top decile of sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
373 of 461 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
558 total, page 5 of 12
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
NCT04046549
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
NCT03971071
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
NCT03362177
Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant
NCT04087720
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
NCT03832998
A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole
NCT04139226
Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
NCT03994731
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
NCT03927144
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03859427
A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
NCT03809663
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
NCT03721172
AMG 404 in Patients With Advanced Solid Tumors
NCT03853109
Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT03836053
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
NCT03777436
A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis
NCT03783026
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
NCT03792841
A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH
NCT03818607
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
NCT03747939
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)
NCT03852472
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
NCT03701763
A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
NCT03817424
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
NCT03757130
Imaging of Coronary Plaques in Participants Treated With Evolocumab
NCT03570697
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
NCT03571828
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
NCT03703908
Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
NCT03635957
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
NCT03541369
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
NCT03465540
A Phase1 Study of VIB9600
NCT03621605
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
NCT03626662
Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
NCT03638128
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
NCT03512353
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
NCT03298412
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
NCT03410056
A Study of CCX140-B in Subjects With FSGS
NCT03536754
Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
NCT03164928
AMG 334 20160172 Pediatric Migraine PK Study.
NCT03499119
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
NCT03422627
Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
NCT03296696
A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment
NCT06004934
Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
NCT03461211
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus
NCT03451422
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
NCT03256344
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT03340766
Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)
NCT03335488
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
NCT03432533
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function
NCT03318809
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
NCT03301857
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03287908
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 216 |
| Phase 2 | 111 |
| Phase 3 | 174 |
| Phase 4 | 38 |
What is open in the Amgen pipeline
55 recruiting of 558 indexed (10% open); 373 completed (67%).
Phase mix: 212 late (III/IV) vs 327 early (I/II) (early-phase heavy).
Top condition: Obesity (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Amgen: open-pipeline peers nationwide
Peers matched on 558 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Amgen sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 558 trials (± recruiting share)
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- University of Maryland, Baltimore · 560 trials · 18% recruiting
- Ohio State University · 552 trials · 21% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Ohio University · 10% recruiting · 51 trials
- Purdue University · 10% recruiting · 141 trials
- University of North Carolina, Chapel Hill · 10% recruiting · 1,109 trials
- Abiomed · 10% recruiting · 20 trials
Related
What to do with this Amgen page
558 registered trials is a research-attention snapshot, not an endorsement of Amgen or any single study.
- 55 of Amgen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Amgen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Amgen pipeline card: 558 registered trials from official public datasets.Report a data error.